Get the Stockscreener App
0.26
3.71%
0.0093
After Hours:
.24
-0.02
-7.69%
AEON Biopharma Inc. stock is traded at $0.26, with a volume of 765.61K.
It is up +3.71% in the last 24 hours and down -63.99% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.2507
Open:
$0.2513
24h Volume:
765.61K
Relative Volume:
0.89
Market Cap:
$11.48M
Revenue:
-
Net Income/Loss:
$-60.11M
P/E Ratio:
-0.0598
EPS:
-4.347
Net Cash Flow:
$-12.04M
1W Performance:
-10.03%
1M Performance:
-63.99%
6M Performance:
-78.33%
1Y Performance:
-67.08%
1-Day Range:
$0.2222
$0.26
1-Week Range:
$0.2222
$0.2968
52-Week Range:
$0.2222
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.26 | 11.07M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
Aeon Biopharma Inc (AEON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aeon Biopharma Inc (AEON) Income Statement - TradingKey
Aeon Biopharma Inc (AEON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards - GlobeNewswire Inc.
Aeon Biopharma Inc (AEON) Balance Sheet - TradingKey
Aeon Biopharma Inc (AEON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aeon Biopharma Inc (AEON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aeon Biopharma Inc (AEON) Cash Flow - TradingKey
Aeon Biopharma Inc (AEON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AEON|Aeon Biopharma Inc|Price:0.251|Chg%:-0.017 - TradingKey
AEON Biopharma, Inc. Revenue Breakdown – BOATS:AEON - TradingView
Aeon Biopharma Inc (AEON) Institutional Confidence - TradingKey
Aeon Biopharma Inc (AEON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AEON|Aeon Biopharma Inc|Price:0.228|Chg%:-0.023 - TradingKey
AEON Biopharma boosts liquidity with additional share sale - TipRanks
Stonepine Capital group discloses 9.9% AEON Biopharma (AEON) ownership via stock and warrants - Stock Titan
AEON Biopharma Inc. (AEON) Hovers Near Support as Bearish Pressure PersistsMutual Fund Flow - dars.gov.et
NFA- today's 8K - Moomoo
AEON Biopharma (NYSE American: AEON) prices $13.75M stock and milestone warrant sale - Stock Titan
AEON Biopharma (NYSE American: AEON) sells stock and milestone-tied warrants - Stock Titan
AEON BiopharmaOffering Includes 42.69 Mln - Moomoo
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding - The Manila Times
AEON Biopharma Could Raise $29.6M More Through Warrants - Stock Titan
AEON Biopharma, Inc. SEC Filing (Jul 14, 2026) - Stock Titan
AEON Biopharma (AEON) Slides 10% Towards Key Support as Selling Pressure IntensifiesFibonacci Time Zone - dars.gov.et
AEON Biopharma (NASDAQ: AEON) revises S-1 filing fee table for milestone warrants - Stock Titan
AEON Biopharma Offering 17.5M Shrs or Pre-Funded Warrants Along With Two-Year and Five-Year Milestone Warrants - Moomoo
Form S-1 Aeon Biopharma Inc For: 8 July By Investing.com - Investing.com Nigeria
AEON Biopharma (AEON) files S-1 for $11M stock sale plus milestone warrants - Stock Titan
AEON Biopharma Q4 2025 Earnings: Wider-Than-Expected Loss Underscores Pre-Revenue ChallengesQuarterly Financial Update - dars.gov.et
AEON Q4 2025 Earnings: Wider Loss Misses Estimates Amid Pre-Revenue StageDownward Estimate Revision - dars.gov.et
AEONAEON Biopharma Inc Latest SEC Filings - Finviz
Price to book forward of AEON Biopharma, Inc. – AMEX:AEON - TradingView
Price to sales forward of AEON Biopharma, Inc. – AMEX:AEON - TradingView
Enterprise value to revenue forward of AEON Biopharma, Inc. – AMEX:AEON - TradingView
AEON Biopharma, Inc. Class A Actuals & Estimates (AMEX:AEON) - TradingView
AEON Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Aeon Biopharma Inc For: 22 June By Investing.com - Investing.com Nigeria
[Form 4] AEON Biopharma, Inc. Insider Trading Activity - Stock Titan
AEON Biopharma (AEON) grants 222,684 RSUs to director Palmisano - Stock Titan
Director at AEON Biopharma (AEON) granted 222,684 RSUs - Stock Titan
AEON Biopharma (AEON) director awarded 222,684 RSUs in equity grant - Stock Titan
Director Carter granted 222,684 RSUs at AEON Biopharma (AEON) - Stock Titan
AEON Biopharma Inc. (AEON) Edges Higher with Resilience Near Key Support LevelsSymmetrical Triangle - dars.gov.et
AEON BIOPHARMA INC (AEON) Stock Chart - ChartMill
AEON Biopharma shareholders approve directors and auditor slate - TipRanks
Aeon Biopharma Inc (AEON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AEON Biopharma, Inc. Elects Each of Marc Forth and Seongsoo Park as Class III Directors of the Company's Board of Directors - marketscreener.com
AEON Biopharma (NYSE: AEON) investors back Class III board slate and KPMG - Stock Titan
Aeon Biopharma Inc (AEON) Valuation: PE, PB & Fair Value Analysis - TradingKey
AEON Biopharma (AEON) Slides 7% as Selling Pressure Intensifies Near $0.67Wave Extension - newsline.com
AEON Biopharma Inc. Stock (AEON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Cap:
|
Volume (24h):